You can teach an old dog new tricks: anti-malarial prevents cancer in mice

New data generated by a team of researchers from St Jude Children’s Research Hospital, Memphis, and Scripps Research Institute, Jupiter, have indicated that the antimalarial drug chloroquine effectively prevents cancer in mouse models of two distinct human cancer syndromes, Burkitt lymphoma and ataxia telangiectasia.

As discussed in the accompanying commentary by Chi Dang, from Johns Hopkins University School of Medicine, Baltimore, these results complement an old epidemiology study suggesting that malarial prophylaxis with chloroquine diminished the incidence of Burkitt lymphoma.

In the study, chloroquine was shown to inhibit the development of Myc-induced lymphomas (a mouse model of Burkitt lymphoma) and to inhibit the development of lymphomas in ATM-deficient mice (a mouse model of ataxia telangiectasia). By contrast, chloroquine did not inhibit the development of lymphomas in p53-deficient mice.

Further analysis indicated that chloroquine induced cellular features of autophagy (self-eating) and mediated its effects by inducing lysosomal stress and provoking a p53-dependent cell death. The authors therefore suggested that modulating autophagy, either using chloroquine or other approaches, might provide a new avenue for the development of anticancer therapeutics.

Source: Journal of Clinical Investigation

Related stories:

Elusive protein protects malaria parasite from heme
Researchers at the Virginia Bioinformatics Institute at Virginia Tech have identified Heme Detoxification Protein, a unique protein encoded in the malaria genome that represents a potential target for developing new malaria drugs.
Elusive protein protects malaria parasite from heme
Researchers at the Virginia Bioinformatics Institute (VBI) at Virginia Tech have identified Heme Detoxification Protein (HDP), a unique protein encoded in the malaria genome that represents a potential target for developing new malaria drugs.
Researchers identify and shut down makers of fake anti-malarial medications
Georgia Institute of Technology researchers were part of a three-continent, multi-organizational effort known as “Operation Jupiter” that successfully identified and shut down manufacturers who were flooding Southeast Asia with counterfeit – and ineffective – anti-malarial drugs.
For treating malaria, less drugs may be best drugs
The current dosage of drugs used in treating malaria may be helping the parasites become resistant to the drugs faster, without improving the long-term outcome in patients. According to evolutionary biologists, studies using mice suggest that the optimal use of the drugs might slow the spread of drug resistance while making the patient just as healthy.
Largest synthetic gene ever built offers insights into anti-malarial drug resistance
Researchers at Georgetown University Medical Center say they are moving closer to understanding why the most lethal form of human malaria has become resistant to drug treatment in the past three decades. They have been able to artificially construct, and then express in yeast, a protozoan gene that contributes to such resistance. And it was no small feat. The gene they laboriously constructed over a two-year period is believed to be the largest 'synthetic' one ever built, and it successfully produces large quantities of the encoded protein, whose function can now be easily studied.

News discussion:

Medicine & Health news